Related Experiment Video
Updated: Jul 2, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
Identification and control of a degradation product in Avapro film-coated tablet: low dose formulation
George Wang1, John D Fiske, Scott P Jennings
1Analytical Research and Development, Research and Development, Bristol-Myers Squibb, New Brunswick, New Jersey, USA.
Abstract:
A degradation product was formed during the long-term stability studies (LTSS) of the low dose formulation of Avapro film-coated tablet. The degradant was identified as the hydroxymethyl derivative (formaldehyde adduct) of the drug substance, irbesartan, based upon analysis with LC/MS, LC/MS/MS, and chromatographic comparison to the synthetic hydroxymethyl degradation product. Laboratory studies demonstrated that the interaction of individual excipients with the drug substance at elevated temperature and polyethylene glycol (PEG) used in the coating material, Opadry II White, leads to the generation of this formaldehyde adduct. Spiking of formaldehyde to the solution of drug substance gradually produced this impurity and the kinetics studies demonstrated that the reaction between formaldehyde and irbesartan is a second order reaction with a rate constant of 2.6 x 10(-4) M(-1)min(-1) at 25 degrees C in an aqueous media. The redevelopment of the formulation by eliminating PEG from the Opadry II White dry-blend system was enabled by understanding the formaldehyde adduct formation.
More Related Videos
05:46Identification of Pharmaceuticals in The Aquatic Environment Using HPLC-ESI-Q-TOF-MS and Elimination of Erythromycin Through Photo-Induced Degradation
Published on: August 1, 2018
09:30Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
Related Concept Videos
Drug Product Stability
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
In Vitro Drug Release Testing: Overview, Development and Validation
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence